Ipilimumab vs Liraglutide
Ipilimumab vs Liraglutide: Overview
This comparison examines the pharmacological differences between Ipilimumab and Liraglutide.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Liraglutide: GLP-1 receptor agonist enhancing insulin secretion.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Liraglutide — 13 hours.
Chemical Properties
Type: Ipilimumab — Antibody; Liraglutide — Protein.